针对KRAS G12C突变结直肠癌的向治疗:进展,挑战和未来的方向
Yang Lin1, Shuai-Hua Cheng1, Di Wang1
1The First Clinical Medical College, Gansu University of Traditional Chinese Medicine Lanzhou 730000, Gansu, China.
American journal of cancer research
|January 12, 2026
概括
克拉斯G12C抑制剂在结直肠癌 (CRC) 中表现有前途,但面临着耐药性和毒性挑战. 未来的研究旨在通过组合疗法和精确治疗的生物标志物识别来提高疗效并克服耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学 是一个学科.
背景情况:
- 结肠直肠癌 (CRC) 是一个主要的全球健康问题.
- 在约40%的CRC病例中存在KRAS突变,其中KRAS G12C占4%.
- 由于具有独特的囊残留物,KRAS G12C突变为新型疗法提供了特定的标.
研究的目的:
- 建立一个知识框架,以优化KRAS G12C突变CRC的临床试验和实践.
- 解决阻碍KRAS G12C抑制剂的临床转化挑战,包括耐药性和毒性.
- 引导未来的研究方向,以提高治疗疗效和患者的治疗结果.
主要方法:
- 关于CRC中KRAS G12C抑制剂的当前研究的综述和综合.
- 分析临床试验数据和发现的挑战.
- 为未来的治疗策略和生物标志物发现制定框架.
主要成果:
- 选择性KRAS G12C抑制剂 (索托拉西布,阿达格拉西布) 显示出早期临床活性.
- 显著的挑战包括内在/获得的耐药性,治疗毒性和缺乏预测生物标志物.
- 需要改进治疗策略和验证的生物标志物是显而易见的.
结论:
- 进一步开发下一代抑制剂和组合疗法至关重要.
- 识别和验证预测生物标志物将使个性化治疗方法成为可能.
- 提高疗效和克服耐药性是推进KRAS G12C突变CRC精度治疗的关键目标.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


